BR0116763A - Human Specific Antibodies for Selective Cancer Therapy - Google Patents

Human Specific Antibodies for Selective Cancer Therapy

Info

Publication number
BR0116763A
BR0116763A BR0116763-4A BR0116763A BR0116763A BR 0116763 A BR0116763 A BR 0116763A BR 0116763 A BR0116763 A BR 0116763A BR 0116763 A BR0116763 A BR 0116763A
Authority
BR
Brazil
Prior art keywords
construct
specifically
target
binding
cancer therapy
Prior art date
Application number
BR0116763-4A
Other languages
Portuguese (pt)
Inventor
Yocheved Hagai
Janette Lazarovits
Daniel Plaksin
Esther Szanthon
Tuvia Peretz
Avigdor Levanon
Rachel Guy
Orly Lipschitz
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Publication of BR0116763A publication Critical patent/BR0116763A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"ANTICORPOS HUMANOS ESPECìFICOS PARA TERAPIA SELETIVA DO C‰NCER". A presente invenção refere-se a um peptídeo ou polipeptídeo consistindo de uma molécula Fv, uma construção da mesma, um fragmento da referida molécula ou da referida construção, ou uma construção de um fragmento tendo características de ligação acentuadas, de modo a ligar-se seletivamente e/ou especificamente a uma célula alvo em favor de outras células, em que a seletividade ou especificidade da ligação é primordialmente determinada por uma primeira região hipervariável e em que o Fv é um scFv ou um dsfv, e tendo, opcionalmente, um ou mais tags. A ligação acentuada refere-se a um sítio de ligação substancialmente exposto e/ou superexpresso sobre um alvo, ou em um alvo, que compreende uma célula em favor de outras células sobre as quais, ou nas quais, o sítio de ligação não é substancialmente disponível e/ou expresso. A invenção refere-se ainda a um método para isolar os referidos peptídeos e polipeptídeos de uma biblioteca de exibição de fagos e às moléculas de ácido nucléico que as codificam. A invenção provê uma composição farmacêutica que compreende o peptídeo ou polipeptídeo e kits para diagnóstico e tratamento de doença, especificamente câncer, mais especificamente leucemia mielóide aguda."SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY". The present invention relates to a peptide or polypeptide consisting of an Fv molecule, a construct thereof, a fragment of said molecule or said construct, or a fragment construct having enhanced binding characteristics, so as to bind selectively and/or specifically to a target cell in favor of other cells, wherein the selectivity or specificity of binding is primarily determined by a first hypervariable region, and wherein the Fv is an scFv or a dsfv, and optionally having one or more more tags. Enhanced binding refers to a substantially exposed and/or overexpressed binding site on a target, or in a target, comprising a cell in favor of other cells on which, or in which, the binding site is not substantially available and/or express. The invention further relates to a method for isolating said peptides and polypeptides from a phage display library and the nucleic acid molecules encoding them. The invention provides a pharmaceutical composition comprising the peptide or polypeptide and kits for diagnosing and treating disease, specifically cancer, more specifically acute myelogenous leukemia.

BR0116763-4A 2000-12-29 2001-12-31 Human Specific Antibodies for Selective Cancer Therapy BR0116763A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
PCT/US2001/049440 WO2002059264A2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Publications (1)

Publication Number Publication Date
BR0116763A true BR0116763A (en) 2004-03-09

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116763-4A BR0116763A (en) 2000-12-29 2001-12-31 Human Specific Antibodies for Selective Cancer Therapy

Country Status (15)

Country Link
EP (1) EP1353937A4 (en)
JP (1) JP2004524023A (en)
KR (1) KR20030091952A (en)
CN (1) CN100374456C (en)
AU (1) AU2002246737B2 (en)
BR (1) BR0116763A (en)
CA (1) CA2433227A1 (en)
CZ (1) CZ20031983A3 (en)
HU (1) HUP0400775A2 (en)
IL (1) IL156690A0 (en)
MX (1) MXPA03005944A (en)
NZ (1) NZ527173A (en)
PL (1) PL365758A1 (en)
RU (1) RU2316564C2 (en)
WO (1) WO2002059264A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678348A (en) * 2002-07-01 2005-10-05 萨文特医药公司 Compositions and methods for therapeutic treatment
RU2006102571A (en) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) SPECIFIC HUMAN ANTIBODIES
KR101193797B1 (en) 2005-04-26 2012-10-23 화이자 인코포레이티드 P-cadherin antibodies
US8580267B2 (en) 2008-12-19 2013-11-12 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
EP2933262B1 (en) * 2010-07-09 2018-05-02 Affibody AB Polypeptides
CN101948534B (en) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 Method for screening antibodies
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
DK3209685T3 (en) * 2014-10-23 2019-07-29 Singh Molecular Medicine Llc SINGLE DOMAIN antibodies directed against intracellular antigens
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
WO2017055635A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
ES2873846T3 (en) * 2015-11-19 2021-11-04 Revitope Ltd Functional Antibody Fragment Complementation for a Two-Component System for Targeted Elimination of Unwanted Cells
BR112019004873A2 (en) * 2016-09-14 2019-06-11 Teneobio Inc cd3 binding antibodies
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
KR100565883B1 (en) * 1997-01-22 2006-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Tissue factor methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
EP1353937A2 (en) 2003-10-22
AU2002246737B2 (en) 2007-03-01
CN100374456C (en) 2008-03-12
WO2002059264A3 (en) 2003-03-06
CN1551886A (en) 2004-12-01
PL365758A1 (en) 2005-01-10
JP2004524023A (en) 2004-08-12
NZ527173A (en) 2006-03-31
RU2316564C2 (en) 2008-02-10
EP1353937A4 (en) 2005-04-13
MXPA03005944A (en) 2005-04-29
HUP0400775A2 (en) 2007-05-02
KR20030091952A (en) 2003-12-03
WO2002059264A2 (en) 2002-08-01
IL156690A0 (en) 2004-01-04
RU2003123100A (en) 2005-03-10
CA2433227A1 (en) 2002-08-01
CZ20031983A3 (en) 2005-07-13

Similar Documents

Publication Publication Date Title
Wang et al. Target identification of natural and traditional medicines with quantitative chemical proteomics approaches
BR0116763A (en) Human Specific Antibodies for Selective Cancer Therapy
BRPI0618399A2 (en) isolated antigen binding region that is specific for cd38, isolated antibody or a functional fragment thereof that is specific for cd38, isolated antibody or a functional fragment thereof, isolated immunoglobulin, heavy chain variable of an isolated antigen binding region, variable light chain from an isolated antigen binding region, isolated nucleic acid sequence, nucleic acid sequence encoding a variable heavy chain from an isolated antigen binding region, nucleic acid sequence, vector, isolated cell, pharmaceutical composition, use of the pharmaceutical composition, method of inducing specific death of cd38-expressing tumor cells, method of detecting specific death of cd38-expressing tumor cells, method of detecting the presence of cd38 in a minipore source tissue or cell , cd38 detection method in a cd3-expressing erythrocyte 8 and diagnostic composition
BRPI0418766A (en) antibodies and molecules derived from these that bind to steap-1 proteins
BRPI0607486A2 (en) humanized l243 antibody, bispecific antibody or antigen binding fragments thereof, pharmaceutical composition, kit and use of said antibodies
BR0307837A (en) Anti-spruce antibodies and their use
BRPI0606790A2 (en) isolated human antibody or antigen binding portion thereof, isolated polypeptide, composition, isolated nucleic acid, host cell expression vector, rabies vaccine, kit, use of an isolated human monoclonal antibody or antigen binding portion thereof, or an effective amount of a composition, a method for identifying an antibody or fragment thereof, antibody or fragment thereof, antibody or fragment thereof, and glycoprotein.
BRPI0412567A (en) isolated human antibody, method of treating a condition caused by increased ngf expression or increased ngf sensitivity in a patient, pharmaceutical composition, method for detecting ngf in a biological sample, nucleic acid molecule, host cell, isolated cell line, ngf-specific binding agent, isolated human antibody or immunologically functional immunoglobulin fragment or antigen binder thereof, polynucleotide, expression vector, medicament for treating a painful disorder or condition associated with increased ngf expression or increased sensitivity to ngf, and, use of a pharmaceutically effective amount of antibody
HRP20170879T1 (en) Differential in tumour gene products and use of same
BRPI0808940A8 (en) human antibody or binding fragment thereof, antigen, polynucleotide, vector, host cell, method for preparing an antibody or immunoglobulin binding fragment or chain (s) thereof, antibody, immunoglobulin chain or binding fragment thereof , composition, uses of the antibody or binding fragment, an antigen, a polynucleotide, a vector, or a cell, and a tumor antigen binding molecule, method for molecular cloning of an antibody, and kit for the diagnosis of a tumor
BR112018015238A2 (en) antibody conjugate, antibody, kit, pharmaceutical composition, and methods for treating or preventing a disease or condition and for diagnosing a disease or condition
BR112014017645A2 (en) immunological molecule; polynucleotide; vector; recombinant cell comprising the vector; method for producing immunological molecule; antibody or antigen binding fragment thereof; pharmaceutical composition; use of the immunological molecule, antibody, antibody binding fragment or pharmaceutical composition; diagnostic method for diagnosing a disease in an individual, wherein the disease is selected from the group consisting of cancer, an autoimmune disease or an infectious disease; assay for diagnosing a disease in a tissue sample taken from an individual; use of an antibody or fragment that specifically binds to sequence no: 10; and diagnostic method for determining whether to use or administer the composition
ATE517922T1 (en) STABILIZED SINGLE-DOMAIN ANTIBODIES IN A PHARMACEUTICAL COMPOSITION DESIGNED FOR INHALATION
BRPI0816117B8 (en) isolated monoclonal antibody or fragment thereof, pharmaceutical composition, kit for treating cholesterol-related disorders, and use of an antigen-binding protein or a monoclonal antibody or fragment thereof
BRPI0417429A (en) isolated monoclonal antibody or an antigen binding portion thereof, composition, immunoconjugate, bispecific molecule, expression vector, host cell, transgenic mouse, hybridoma, and methods of inhibiting an inflammatory or autoimmune response, treating an inflammatory or autoimmune disease, treating a viral or bacterial infection and preparing an anti-ip-10 antibody
AR012035A1 (en) METHOD FOR DETECTING PROSTATE CANCER, METHOD FOR MONITORING DEVELOPMENT OF PROSTATE CANCER, MONOCLONAL ANTIBODY THAT JOINS A POLYPEPTIDE, AN EFFECTIVE THERAPEUTIC AMOUNT OF MONOCLONAL ANTIBODIES TO PREPARE MEDICINES AND EQUIPMENT FOR
BRPI0607757A2 (en) antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, hybridoma, method for preparing an anti-psma antibody, and, uses of an antibody, or antigen binding portion thereof
BRPI0715660B8 (en) isolated antibody that binds to human IL-31; and, use of a monoclonal antibody
BR112012013915A8 (en) anti-c4 antibodies. 4a and uses thereof
BR9808863A (en) Peptide antiestrogenic compositions and methods to treat breast cancer
De Lorenzo et al. Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
ATE148168T1 (en) MONOCLONAL ANTIBODIES
BR0210905A (en) Specific Antibodies for cd44v6
Shen et al. Discovery of HB-EGF binding peptides and their functional characterization in ovarian cancer cell lines
BR112023015191A2 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SAVIENT PHARMACEUTICALS, INC. (US)

Free format text: ALTERADO DE: BIO-TECHNOLOGY GENERAL CORPORATION

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011.